Published in Health Care Manag Sci on December 01, 2012
Risk stratification in prostate cancer screening. Nat Rev Urol (2012) 1.13
Note on "simulation optimization of PSA-threshold based prostate cancer screening policies". Health Care Manag Sci (2013) 0.75
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94
Mortality results from a randomized prostate-cancer screening trial. N Engl J Med (2009) 30.05
Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst (2003) 11.27
Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2006) 9.91
Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med (2008) 8.14
Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol (2000) 7.94
Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ (2010) 7.15
American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin (2010) 6.45
Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst (2009) 6.07
Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin (2010) 4.76
Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol (2006) 4.64
Gains in life expectancy from medical interventions--standardizing data on outcomes. N Engl J Med (1998) 4.47
Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst (2007) 3.70
Prostate-specific antigen (PSA) best practice policy. American Urological Association (AUA). Oncology (Williston Park) (2000) 3.68
Why is prostate cancer screening so common when the evidence is so uncertain? A system without negative feedback. Am J Med (2002) 3.02
United States life tables, 2006. Natl Vital Stat Rep (2010) 3.01
HALYS and QALYS and DALYS, Oh My: similarities and differences in summary measures of population Health. Annu Rev Public Health (2001) 2.91
Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer (2004) 2.61
Prostate cancer detection with office based saturation biopsy in a repeat biopsy population. J Urol (2004) 2.12
Reassessing the diagnostic yield of saturation biopsy of the prostate. Eur Urol (2007) 2.12
Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach. Med Decis Making (2008) 2.06
Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. JAMA (2000) 1.89
American College of Preventive Medicine practice policy. Screening for prostate cancer in American men. Am J Prev Med (1998) 1.74
The impact of prostate biopsy and periprostatic nerve block on erectile and voiding function: a prospective study. J Urol (2010) 1.73
Trends in reporting Gleason score 1991 to 2001: changes in the pathologist's practice. Eur Urol (2005) 1.57
Utility of saturation biopsy to predict insignificant cancer at radical prostatectomy. Urology (2005) 1.46
A 64-year-old man with low-risk prostate cancer: review of prostate cancer treatment. JAMA (2009) 1.44
Optimal Breast Biopsy Decision-Making Based on Mammographic Features and Demographic Factors. Oper Res (2010) 1.34
Patient and community preferences for outcomes in prostate cancer: implications for clinical policy. Med Care (2003) 1.23
Biopsy standards for detection of prostate cancer. World J Urol (2007) 1.10
A review and meta-analysis of prostate cancer utilities. Med Decis Making (2007) 1.03
Prostate biopsy: how many cores are enough? Urol Oncol (2003) 1.00
Use of extended systematic sampling in patients with a prior negative prostate needle biopsy. J Urol (2002) 1.00
Optimization of PSA screening policies: a comparison of the patient and societal perspectives. Med Decis Making (2011) 0.96
Screening for prostate cancer: evidence and perspectives. BJU Int (2001) 0.96
Serial prostate specific antigen screening for prostate cancer: a computer model evaluates competing strategies. J Urol (1999) 0.95
The independent impact of extended pattern biopsy on prostate cancer stage migration. J Urol (2005) 0.94
A population-based study of pain and quality of life during the year before death in men with prostate cancer. Br J Cancer (2004) 0.91
Optimization of cervical cancer screening. Cancer Causes Control (1992) 0.90
Conservative management of prostate cancer. N Engl J Med (1994) 0.77
Exposure to low-dose ionizing radiation from medical imaging procedures. N Engl J Med (2009) 11.51
A randomized controlled trial of telemonitoring in older adults with multiple health issues to prevent hospitalizations and emergency department visits. Arch Intern Med (2012) 5.00
Regulatory review of novel therapeutics--comparison of three regulatory agencies. N Engl J Med (2012) 4.50
The diabetes mellitus medication choice decision aid: a randomized trial. Arch Intern Med (2009) 4.41
When choosing statin therapy: the case for generics. JAMA Intern Med (2013) 3.80
Hospitalizations after heart failure diagnosis a community perspective. J Am Coll Cardiol (2009) 3.42
CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res (2008) 3.40
Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care (2012) 3.24
Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy. Cancer (2006) 3.08
Second-line agents for glycemic control for type 2 diabetes: are newer agents better? Diabetes Care (2014) 2.99
Off-hour presentation and outcomes in patients with acute myocardial infarction: systematic review and meta-analysis. BMJ (2014) 2.87
Thromboembolism and bleeding in bladder cancer. Oncology (Williston Park) (2014) 2.66
Bladder cancer. J Natl Compr Canc Netw (2013) 2.46
Risk-stratification methods for identifying patients for care coordination. Am J Manag Care (2013) 2.40
Oct4 pseudogenes are transcribed in cancers. Biochem Biophys Res Commun (2005) 2.34
Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue. Proc Natl Acad Sci U S A (2013) 2.29
Cumulative exposure to ionizing radiation from diagnostic and therapeutic cardiac imaging procedures: a population-based analysis. J Am Coll Cardiol (2010) 2.26
B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res (2007) 2.19
Lifetime costs of medical care after heart failure diagnosis. Circ Cardiovasc Qual Outcomes (2010) 2.19
Cumulative complexity: a functional, patient-centered model of patient complexity can improve research and practice. J Clin Epidemiol (2012) 2.16
Variation in treatment recommendations of adjuvant radiation therapy for high-risk prostate cancer by physician specialty. Urology (2013) 2.16
The chest pain choice decision aid: a randomized trial. Circ Cardiovasc Qual Outcomes (2012) 2.15
Perceptions of Active Surveillance and Treatment Recommendations for Low-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists. Med Care (2014) 2.14
Reassessing the diagnostic yield of saturation biopsy of the prostate. Eur Urol (2007) 2.12
A prospective evaluation of computerized tomographic (CT) scanning as a screening modality for esophageal varices. Hepatology (2008) 2.02
The relationship of the intensity of posttreatment prostate-specific antigen surveillance and prostate cancer outcomes: results from a population-based cohort. Mayo Clin Proc (2012) 2.00
Urachal anomalies: a longitudinal study of urachal remnants in children and adults. J Urol (2007) 1.99
Generic atorvastatin and health care costs. N Engl J Med (2011) 1.95
The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. Eur Urol (2011) 1.90
Use of a decision aid to improve treatment decisions in osteoporosis: the osteoporosis choice randomized trial. Am J Med (2011) 1.84
Factors associated with 30-day readmission rates after percutaneous coronary intervention. Arch Intern Med (2011) 1.70
A facile approach to anhydrogalactosucrose derivatives from chlorinated sucrose. Carbohydr Res (2004) 1.59
The implications of hospital acquired adverse events on mortality, length of stay and costs for patients undergoing radical cystectomy for bladder cancer. J Urol (2012) 1.58
Contemporary trends in nephrectomy for renal cell carcinoma in the United States: results from a population based cohort. J Urol (2011) 1.57
A systematic review and meta-analysis of randomized trials of carotid endarterectomy vs stenting. J Vasc Surg (2011) 1.56
Hyperthermia as a treatment for bladder cancer. Oncology (Williston Park) (2010) 1.56
Hospitalization costs for radical prostatectomy attributable to robotic surgery. Eur Urol (2012) 1.53
Disparities in access to hospitals with robotic surgery for patients with prostate cancer undergoing radical prostatectomy. J Urol (2012) 1.53
Integration of light and abscisic acid signaling during seed germination and early seedling development. Proc Natl Acad Sci U S A (2008) 1.52
Effect of premium, copayments, and health status on the choice of health plans. Med Care (2008) 1.48
Chronic care model and shared care in diabetes: randomized trial of an electronic decision support system. Mayo Clin Proc (2008) 1.45
Third prize: the role of endoscopic nephron-sparing surgery in the management of upper tract urothelial carcinoma. J Endourol (2011) 1.45
Projecting future drug expenditures--2004. Am J Health Syst Pharm (2004) 1.45
Increasing frequency of opioid prescriptions for chronic abdominal pain in US outpatient clinics. Clin Gastroenterol Hepatol (2011) 1.44
What have we learnt from the rosiglitazone saga? BMJ (2011) 1.44
Determinants of fluoroscopy time for invasive coronary angiography and percutaneous coronary intervention: insights from the NCDR(®). Catheter Cardiovasc Interv (2013) 1.43
Impact of a drug utilization review program on high-risk use of prescription controlled substances. Pharmacoepidemiol Drug Saf (2013) 1.42
An examination of the dynamic changes in prostate-specific antigen occurring in a population-based cohort of men over time. BJU Int (2012) 1.42
Hydrogen-rich saline attenuates lung ischemia-reperfusion injury in rabbits. J Surg Res (2011) 1.41
Effect of multiple chronic conditions among working-age adults. Am J Manag Care (2011) 1.41
Ambulatory diagnosis and treatment of nonmalignant pain in the United States, 2000-2010. Med Care (2013) 1.40
Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clin Cancer Res (2011) 1.38
Early detection of prostate cancer local recurrence by urinary prostate-specific antigen. Can Urol Assoc J (2009) 1.38
Projecting future drug expenditures--2012. Am J Health Syst Pharm (2012) 1.37
Dextranomer/hyaluronic acid for pediatric vesicoureteral reflux: systematic review. Pediatrics (2010) 1.36
Shared decision making for patients with type 2 diabetes: a randomized trial in primary care. BMC Health Serv Res (2013) 1.26
Obesity and survival after radical prostatectomy: A 10-year prospective cohort study. Cancer (2006) 1.26
BAS1 and SOB7 act redundantly to modulate Arabidopsis photomorphogenesis via unique brassinosteroid inactivation mechanisms. Plant J (2005) 1.23
Effect of weekend hospital admission on gastrointestinal hemorrhage outcomes. Dig Dis Sci (2009) 1.22
Impact of the 2008-2009 economic recession on screening colonoscopy utilization among the insured. Clin Gastroenterol Hepatol (2011) 1.21
Out of context: clinical practice guidelines and patients with multiple chronic conditions: a systematic review. Med Care (2014) 1.20
Self-report of hypoglycemia and health-related quality of life in patients with type 1 and type 2 diabetes. Endocr Pract (2013) 1.20
Care management for Type 2 diabetes in the United States: a systematic review and meta-analysis. BMC Health Serv Res (2012) 1.19
Projecting future drug expenditures: 2011. Am J Health Syst Pharm (2011) 1.16
Risk models and patient-centered evidence: should physicians expect one right answer? JAMA (2012) 1.15
Toolboxes for a standardised and systematic study of glycans. BMC Bioinformatics (2014) 1.15
Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine. J Immunol (2007) 1.14
Medication adherence among community-dwelling patients with heart failure. Mayo Clin Proc (2011) 1.14
Protocol for the Osteoporosis Choice trial. A pilot randomized trial of a decision aid in primary care practice. Trials (2009) 1.12
Preparation and histological evaluation of biomimetic three-dimensional hydroxyapatite/chitosan-gelatin network composite scaffolds. Biomaterials (2002) 1.10
Hierarchical recruitment into nascent ribosomes of assembly factors required for 27SB pre-rRNA processing in Saccharomyces cerevisiae. Nucleic Acids Res (2012) 1.09
A randomized controlled trial of telemonitoring in older adults with multiple chronic conditions: the Tele-ERA study. BMC Health Serv Res (2010) 1.09
Interpreting a study on bladder cancer screening. Eur Urol (2013) 1.08
Individuals with diabetes preferred that future trials use patient-important outcomes and provide pragmatic inferences. J Clin Epidemiol (2010) 1.06
Depression, healthcare utilization, and death in heart failure: a community study. Circ Heart Fail (2013) 1.04
Outcomes of metallic stents for malignant ureteral obstruction. J Urol (2012) 1.02
The effects of incremental costs of smoking and obesity on health care costs among adults: a 7-year longitudinal study. J Occup Environ Med (2012) 1.02
Projecting future drug expenditures in U.S. nonfederal hospitals and clinics--2013. Am J Health Syst Pharm (2013) 1.02
Effectiveness of the head CT choice decision aid in parents of children with minor head trauma: study protocol for a multicenter randomized trial. Trials (2014) 1.01
Rationale and design of the Exercise Intensity Trial (EXCITE): A randomized trial comparing the effects of moderate versus moderate to high-intensity aerobic training in women with operable breast cancer. BMC Cancer (2010) 1.00
Impact of new drugs and biologics on colorectal cancer treatment and costs. J Oncol Pract (2011) 1.00
Comprehensive handbook for developing a bladder cancer cystectomy database. Urol Oncol (2011) 0.99
Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis. J Natl Compr Canc Netw (2013) 0.98
Contemporary epidemiological trends in complex congenital genitourinary anomalies. J Urol (2013) 0.97
Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase. Antimicrob Agents Chemother (2012) 0.97
Optimizing the start time of statin therapy for patients with diabetes. Med Decis Making (2009) 0.97
Penile cancer: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2013) 0.97
The impact of decision aids to enhance shared decision making for diabetes (the DAD study): protocol of a cluster randomized trial. BMC Health Serv Res (2012) 0.96
Good research practices for measuring drug costs in cost-effectiveness analyses: a managed care perspective: the ISPOR Drug Cost Task Force report--Part III. Value Health (2009) 0.96
Optimization of PSA screening policies: a comparison of the patient and societal perspectives. Med Decis Making (2011) 0.96
Impact of physician assistant care on office visit resource use in the United States. Health Serv Res (2008) 0.94
Recollection of childhood abdominal pain in adults with functional gastrointestinal disorders. Scand J Gastroenterol (2009) 0.94
Clinician's use of the Statin Choice decision aid in patients with diabetes: a videographic study nested in a randomized trial. J Eval Clin Pract (2009) 0.94
Direct medical costs in patients with fibromyalgia: Cost of illness and impact of a brief multidisciplinary treatment program. Am J Phys Med Rehabil (2011) 0.94
Projecting future drug expenditures--2008. Am J Health Syst Pharm (2008) 0.93